Kenneth Hoberman Sells 25,101 Shares of Stemline Therapeutics Inc (STML) Stock
Stemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman sold 25,101 shares of Stemline Therapeutics stock in a transaction on Monday, March 11th. The stock was sold at an average price of $11.11, for a total transaction of $278,872.11. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Kenneth Hoberman also recently made the following trade(s):
- On Thursday, March 7th, Kenneth Hoberman sold 2,995 shares of Stemline Therapeutics stock. The stock was sold at an average price of $11.36, for a total transaction of $34,023.20.
- On Monday, February 25th, Kenneth Hoberman sold 10,557 shares of Stemline Therapeutics stock. The stock was sold at an average price of $12.05, for a total transaction of $127,211.85.
- On Tuesday, January 8th, Kenneth Hoberman sold 13,547 shares of Stemline Therapeutics stock. The stock was sold at an average price of $10.15, for a total transaction of $137,502.05.
NASDAQ STML opened at $13.62 on Friday. The firm has a market cap of $433.13 million, a PE ratio of -4.63 and a beta of 1.12. Stemline Therapeutics Inc has a one year low of $7.82 and a one year high of $20.55.
STML has been the topic of a number of recent analyst reports. Piper Jaffray Companies reiterated an “overweight” rating on shares of Stemline Therapeutics in a research note on Wednesday, February 6th. Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 5th. HC Wainwright reiterated a “buy” rating and set a $38.00 target price on shares of Stemline Therapeutics in a research note on Wednesday, December 26th. ValuEngine upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 23rd. Finally, BidaskClub cut Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 29th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $25.40.
ILLEGAL ACTIVITY WARNING: “Kenneth Hoberman Sells 25,101 Shares of Stemline Therapeutics Inc (STML) Stock” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/kenneth-hoberman-sells-25101-shares-of-stemline-therapeutics-inc-stml-stock/2896777.html.
About Stemline Therapeutics
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Read More: How Do Front-End Loads Impact an Investment?
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.